Colorectal cancer following tamoxifen therapy for breast cancer (United States) |
| |
Authors: | Linda S Cook Noel S Weiss Nikolas Pharris-Ciurej Stephen M Schwartz Emily White |
| |
Institution: | (1) Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;(2) Department of Epidemiology, University of Washington, Seattle, WA, USA |
| |
Abstract: | Background: An analysis combining data from several clinical trials has raised concern that tamoxifen therapy may increase the risk of a subsequent colorectal malignancy. We conducted a nested case–control study to test this hypothesis.
Methods: A cohort of women diagnosed with breast cancer in 1978–1992 was identified from the western Washington population-based cancer registry. Cases included women who subsequently developed colorectal cancer prior to 1995. Controls were a random sample of the cohort who did not develop a second primary malignancy, matched to cases on age, stage, and year of initial cancer diagnosis. Tamoxifen use was ascertained by medical record abstraction and physician questionnaires.
Results: Thirty-six percent of the 122 cases for whom information could be obtained received tamoxifen versus 38% of 194 controls. Relative to non-users and adjusted for receipt of other therapies, there was no increased risk of colorectal cancer associated with tamoxifen use in general (matched odds ratio mOR] = 0.9, 95% CI 0.6–1.6), longer durations of use (for 37months, mOR = 0.8, 95% CI 0.4–1.9), higher cumulative doses of therapy (for 15 g, mOR = 0.8, 95% CI 0.4–1.6), or use that started at least 5 years prior to the end of study follow-up (mOR = 1.1, 95% CI 0.3–3.7).
Conclusions: We found no overall increased risk for colorectal cancer among tamoxifen users. |
| |
Keywords: | breast cancer colorectal cancer second primary cancer tamoxifen |
本文献已被 SpringerLink 等数据库收录! |
|